The review covers various organelle-specific autophagy types but doesn't address what molecular mechanisms determine which organelles are selectively targeted for autophagy in neurodegeneration. This selectivity mechanism is crucial for understanding disease progression and therapeutic intervention.
Gap type: open_question
Source paper: Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles. (2021, Autophagy, PMID:32048886)
Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
10 citations10 with PMIDValidation: 0%5 supporting / 5 opposing
✓For(5)
No supporting evidence
No opposing evidence
(5)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
7
1
2
MECH 7CLIN 1GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
TREM2 loss-of-function mutations increase AD risk …
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-21 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Therapeutic Hypotheses: Organelle-Specific Autophagy Selectivity in Neurodegeneration
Hypothesis 1: Calcineurin-FUNDC1 Axis as a Master Switch for Mitophagy vs. Apoptotic Cell Death
Title: Calcineurin-mediated FUNDC1 dephosphorylation directs damaged mitochondria toward apoptosis rather than mitophagy in neurodegeneration
Mechanism: In neurons experiencing mitochondrial stress, sustained elevation of mitochondrial Ca²⁺ triggers calcineurin activation, which dephosphorylates FUNDC1 at S13. This converts FUNDC1 from a mitophagy repressor to an activator—but paradoxically, in
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Hypotheses
Hypothesis 1: Calcineurin-FUNDC1 Axis
Weak Links
Mechanistic contradiction is unresolved. The cited FUNDC1 paper (PMID: 23933753) demonstrates that calcineurin-mediated FUNDC1 dephosphorylation promotes mitophagy—this is the direct opposite of the MOMP induction claimed. The "paradox" in the neurodegenerative context is asserted, not mechanistically explained. FUNDC1 dephosphorylation does not intrinsically specify "mitophagy vs. apoptosis"; the model requires an additional unspecified checkpoint.
**Beclin-1 cleavage attribution i
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Feasibility Assessment: Organelle-Specific Autophagy Selectivity in Neurodegeneration
Overview
Both hypotheses survive the skeptic's critique sufficiently to warrant continued experimental testing, but with significant revisions. Neither represents a near-term therapeutic target as originally framed. The path forward requires decoupling the speculative therapeutic claim from the legitimate mechanistic question.
Hypothesis 1: Calcineurin-FUNDC1 Axis
Druggability
Calcineurin (PPP3CA): High tractability historically — FK506 and cyclosporine A are FDA-approved with w
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼